.jpg?format=webp&width=780)
To assess composite endpoints combining glycaemic control with weight loss and without hypoglycaemia with tirzepatide in type 2 diabetes (T2D). Across the SURPASS‐1 to ‐5 clinical trials, more tirzepatide‐treated participants with T2D achieved clinically meaningful composite endpoints, which included reaching glycaemic targets with various degrees of weight loss and without hypoglycaemia than those in the comparator groups.
Like
Save
Share